CXCR3及其配体I-TAC在免疫性血小板减少性紫癜发病中的作用
发布时间：2019-06-29 07:52
【摘要】：目的探讨CXC亚族趋化因子受体3（CXCR3）及其配体I-TAC在免疫性血小板减少性紫癜（ITP）发病机制中的作用以及免疫抑制剂治疗后的水平。 方法应用酶联免疫吸附试验（ELISA）和实时定量PCR（RT-PCR）法，对30例初诊及复发ITP患者治疗前、18例治疗有效患者和24例健康人的血浆γ-干扰素（IFN-γ）、I-TAC的含量和外周血单个核细胞（PBMNC）CXCR3的相对表达进行检测。 结果（1）治疗前ITP患者血浆中IFN-γ的含量（71.45±17.62）pg/ml明显高于治疗有效组（36.9±14.9）pg/ml与正常对照组（25.28±12.85）pg/ml（P0.05），ITP治疗有效组血浆IFN-γ的含量仍高于正常对照组（P0.05）。（2）治疗前ITP患者血浆中I-TAC的含量（455.56±144.70）pg/ml与治疗有效组（488.24±164.70）pg/ml及正常对照组（382.97±167.43）pg/ml相比，三者之间无统计学意义（P0.05）。（3）与正常对照（相对表达中位数为0.12倍）（0.04，，0.28）相比，治疗前（相对表达中位数为6.76倍）（3.03，37.00）与治疗有效组（相对表达中位数为1.76倍）（0.45，14.18）ITP患者PBMNC高表达CXCR3mRNA（P0.05），治疗有效后CXCR3表达降低，但与治疗前组对比差异无统计学意义（P0.05）。 结论ITP患者表现Th1型细胞因子优势同时，CXCR3+细胞可能通过趋化机制在ITP免疫机制中发挥一定的作用。另外，免疫抑制治疗对该作用轴有一定的影响。
[Abstract]:Objective to investigate the role of CXC subfamily chemokine receptor 3 (CXCR3) and its ligand I-TAC in the pathogenesis of immune thrombocytopenic purpura (ITP) and the level of immunosuppressive agents. Methods enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR (RT-PCR) were used to detect the content of plasma interferon-gamma (IFN- 纬), I-TAC and the relative expression of (PBMNC) CXCR3 in peripheral blood mononuclear cells in 30 patients with newly diagnosed and recurrent ITP, 18 patients with effective treatment and 24 healthy controls. Results (1) the content of IFN- 纬 in plasma of patients with ITP before treatment (41.45 卤17.62) pg/ml was significantly higher than that of effective group (36.9 卤14.9) pg/ml and normal control group (25.28 卤12.85) pg/ml (P 0.05). The content of plasma IFN- 纬 in the effective group of ITP was still higher than that in the normal control group (P 0.05). (2). The content of I-TAC in the plasma of ITP patients before treatment was (455.56 卤144.70) pg/ml, which was higher than that of the effective group (488.24 卤164.70) pg/ml and the normal control group (382.97 卤167.43) pg/ml. There was no significant difference among the three groups (P 0.05,). (3) compared with the normal control (the median relative expression was 0. 12 times) (0. 04, 0. 28). Before treatment (the median relative expression was 6. 76 times) (3.03, 37. 00) and the therapeutic effective group (1. 76 times) (0. 45,14. 18), the expression of CXCR3mRNA in PBMNC of ITP patients was lower than that of the control group (0. 45, 14. 18), and the expression of CXCR3 was decreased after treatment. However, there was no significant difference between the pre-treatment group and the pre-treatment group (P 0.05). Conclusion ITP patients show Th1 cytokine dominance, and CXCR3 cells may play a role in the immune mechanism of ITP through chemotactic mechanism. In addition, immunosuppressive therapy has a certain effect on the axis of action.
【学位授予单位】：青海大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R392
本文编号：2507669
[Abstract]:Objective to investigate the role of CXC subfamily chemokine receptor 3 (CXCR3) and its ligand I-TAC in the pathogenesis of immune thrombocytopenic purpura (ITP) and the level of immunosuppressive agents. Methods enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR (RT-PCR) were used to detect the content of plasma interferon-gamma (IFN- 纬), I-TAC and the relative expression of (PBMNC) CXCR3 in peripheral blood mononuclear cells in 30 patients with newly diagnosed and recurrent ITP, 18 patients with effective treatment and 24 healthy controls. Results (1) the content of IFN- 纬 in plasma of patients with ITP before treatment (41.45 卤17.62) pg/ml was significantly higher than that of effective group (36.9 卤14.9) pg/ml and normal control group (25.28 卤12.85) pg/ml (P 0.05). The content of plasma IFN- 纬 in the effective group of ITP was still higher than that in the normal control group (P 0.05). (2). The content of I-TAC in the plasma of ITP patients before treatment was (455.56 卤144.70) pg/ml, which was higher than that of the effective group (488.24 卤164.70) pg/ml and the normal control group (382.97 卤167.43) pg/ml. There was no significant difference among the three groups (P 0.05,). (3) compared with the normal control (the median relative expression was 0. 12 times) (0. 04, 0. 28). Before treatment (the median relative expression was 6. 76 times) (3.03, 37. 00) and the therapeutic effective group (1. 76 times) (0. 45,14. 18), the expression of CXCR3mRNA in PBMNC of ITP patients was lower than that of the control group (0. 45, 14. 18), and the expression of CXCR3 was decreased after treatment. However, there was no significant difference between the pre-treatment group and the pre-treatment group (P 0.05). Conclusion ITP patients show Th1 cytokine dominance, and CXCR3 cells may play a role in the immune mechanism of ITP through chemotactic mechanism. In addition, immunosuppressive therapy has a certain effect on the axis of action.
【学位授予单位】：青海大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R392
【参考文献】
相关期刊论文 前4条
1 郑红;趋化因子及其受体的功能[J];免疫学杂志;2004年01期
2 姜培娟;林其德;鲍世民;赵爱民;肖世金;;趋化因子受体CCR3、CCR5和CXCR3与自然流产的相关性[J];上海交通大学学报(医学版);2008年12期
3 王晨超;郭澍;唐明睿;肖汀;于学伟;张欣;吴剑;王凯波;;I-TAC和MDC在病理性瘢痕中的表达及意义[J];中国美容整形外科杂志;2008年05期
4 冀林华;任汉云;石永进;岑溪南;邱志祥;欧晋平;许蔚林;;血浆炎性趋化因子CXCL9/Mig水平与急性移植物抗宿主病关系的研究[J];中国实验血液学杂志;2006年06期
本文编号：2507669
本文链接：https://www.wllwen.com/xiyixuelunwen/2507669.html
最近更新
教材专著
